WFU researchers discover new hemoglobin function

November 04, 2007

A team of researchers from Wake Forest University, the National Institutes of Health and other institutions has discovered a previously undetected chemical process within the oxygen-carrying molecule hemoglobin that could have far-reaching implications for the treatment of cardiovascular diseases.

In a paper published online Nov. 4 in the journal Nature Chemical Biology, senior authors Daniel Kim-Shapiro, professor of physics at Wake Forest, and Mark Gladwin, chief of the Vascular Medicine Branch of the National Heart, Lung and Blood Institute of the NIH, describe how hemoglobin, through a catalytic reaction that does not change its own chemical properties, converts nitrite salt to the vasodilator nitric oxide. The paper further documents how the nitric oxide activity harnessed by hemoglobin escapes the red blood cell to regulate blood flow and how the process, surprisingly, relies on the oxidized, or rusted, form of hemoglobin, previously associated only with diseased states.

"We believe we have solved the paradox of how hemoglobin mediates the conversion of nitrite to nitric oxide in a way that it is not immediately destroyed in the red cell and so it can be effective biologically," Kim-Shapiro says.

In the bloodstream, iron-rich hemoglobin consumes, on contact, any free nitric oxide released by the blood vessels, so the idea that hemoglobin participates in forming nitric oxide had seemed implausible until recently.

In 2003, Gladwin and collaborators at the NIH, Wake Forest and the University of Alabama discovered that nitrite salt, the same substance used to cure meat and previously thought to be biologically inert, serves in the cell as a storage pool for nitric oxide. Since then, nitrite has been the object of intense study by researchers worldwide in pursuit of new treatments for such conditions as sickle cell disease, myocardial infarction, pulmonary hypertension, stroke and atherosclerosis.

In the most recent study, the researchers conclude that the nitrite-hemoglobin reaction generates dinitrogen trioxide (N2O3), which takes one of several pathways from the red blood cell and later separates into nitric oxide (NO) and nitrogen dioxide (NO2).

The newly discovered chemistry in hemoglobin has eluded scientists for a century because the intermediate molecule, nitrite-methemoglobin, formed during the process cannot be observed by electron paramagnetic resonance spectroscopy, the most sophisticated analysis technique currently available. That has rendered the reaction "invisible" by direct observation, but indirect measurement of the process is possible.

"Using a variety of biophysical techniques and by careful examination of the rates of reactions and the products that are made when experimenting with hemoglobin and nitrite, we were able to discover this reaction mechanism," Kim-Shapiro explains.
-end-
The research was funded by grants from the NIH.

An abstract of the paper can be accessed at http://dx.doi.org by entering the digital object identifier number 10.1038/nchembio.2007.46.

Also contributing to the study were Swati Basu, research assistant professor of physics at Wake Forest; Rozalina Grubina, a Howard Hughes Scholar in Gladwin's NIH laboratory; S. Bruce King, professor of chemistry at Wake Forest; Jinming Huang, research assistant professor of chemistry at Wake Forest; Xiaojun He, postdoctoral fellow in physics at Wake Forest; Wake Forest graduate students Ivan Azarov and Anne Jeffers; Wake Forest undergraduate students Atul Mehta and Ryan Seibert; Wake Forest visiting undergraduate student Alice Jiang; Zhi Huang, a postdoctoral fellow in Gladwin's NIH laboratory, Jeanet Conradie, senior lecturer at the University of the Free State in South Africa; Rakesh Patel, associate professor of pathology at the University of Alabama at Birmingham; Neil Hogg, associate professor of biophysics at the Medical College of Wisconsin in Milwaukee; and Abhik Ghosh, professor of chemistry at the University of Tromsø in Norway.

Wake Forest University

Related Pulmonary Hypertension Articles from Brightsurf:

New virtual screening tool eases, accelerates routine diagnosis of pulmonary hypertension
The COVID-19 pandemic has increasing numbers of doctors caring for patients virtually.

Adding another dimension to a cell culture model for pulmonary arterial hypertension
Pulmonary arterial hypertension is a rare disease in which excessive proliferation of the cells of pulmonary arterial walls obstructs the blood flow in the lungs.

Casting a wider net to catch more cases of pulmonary hypertension
Investigators took an evidence-based approach to determine the lower end of the risk spectrum for PH based on pulmonary vascular resistance (PVR), which is resistance against blood flow from the pulmonary artery to the lungs.

Fusion protein holds promise for treating pulmonary arterial hypertension
In a paper published in Science Translational Medicine, researchers illuminate the underlying biological pathways that may lead to vessel destruction in pulmonary arterial hypertension.

New technical approach can enhance diagnosis of pulmonary hypertension
The management and prognosis of pulmonary hypertension heavily relies on whether the pathology is localized in pulmonary arteries or veins.

LSU Health study suggests nicotine exposure alone leads to pulmonary hypertension
A study conducted at LSU Health New Orleans has shown for the first time that chronic exposure to inhaled nicotine alone increases blood pressure in both the body's general circulation and in the lungs that can lead to pulmonary hypertension.

Specific gut bacteria may be associated with pulmonary arterial hypertension
Researchers have found a specific bacterial profile in the gut of people with pulmonary arterial hypertension, a chronic and progressive disease that causes constriction of arteries in the lungs.

Advancing an oral drug for pulmonary arterial hypertension
With a protein drug grown in the leaves of lettuce plants, the University of Pennsylvania's Henry Daniell and colleagues hope to provide new treatment options for patients with pulmonary arterial hypertension, a rare but deadly disease.

Antiarrhythmic drug identified as potential treatment for pulmonary arterial hypertension
High blood pressure in the lungs, known as pulmonary arterial hypertension (PAH), is a potentially fatal disease caused by obstruction of blood flow in the lungs.

Pulmonary arterial hypertension targeted for new treatment by Sheffield scientists
Scientists at the University of Sheffield, working in collaboration with drug and vaccine developer Kymab Ltd, Cambridge, have identified a novel antibody that has the potential to become a new treatment for pulmonary arterial hypertension (PAH).

Read More: Pulmonary Hypertension News and Pulmonary Hypertension Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.